Value of serum lactate dehydrogenase, β<sub>2</sub> microglobulin and ferritin combined with modified WHO-based Prognostic Scoring System in predicting poor prognosis of myelodysplastic syndrome

WAN Jiangwei; CHENG Dongru; WANG Tao; GAO Ping

doi:10.7619/jcmp.20233107

Journal of Clinical Medicine in Practice > 2024 > 28(5): 79-84. > DOI: 10.7619/jcmp.20233107

WAN Jiangwei, CHENG Dongru, WANG Tao, GAO Ping. Value of serum lactate dehydrogenase, β₂ microglobulin and ferritin combined with modified WHO-based Prognostic Scoring System in predicting poor prognosis of myelodysplastic syndrome[J]. Journal of Clinical Medicine in Practice, 2024, 28(5): 79-84. DOI: 10.7619/jcmp.20233107

Citation:

PDF (997 KB)

Value of serum lactate dehydrogenase, β₂ microglobulin and ferritin combined with modified WHO-based Prognostic Scoring System in predicting poor prognosis of myelodysplastic syndrome

Department of Hematology and Oncology, the First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Zhengzhou, Henan, 450000

More Information

Received Date: September 27, 2023
Revised Date: December 25, 2023
Available Online: March 21, 2024

Graphical Abstract

Abstract

Abstract

Objective
To investigate the value of serum lactate dehydrogenase (LDH), β₂-microglobulin (β₂-MG) and serum ferritin (SF) combined with the modified WHO-based Prognostic Scoring System (WPSS) score in predicting poor prognosis of patients with myelodysplastic syndrome (MDS).
Methods
A total of 110 patients with MDS were selected as the research objects, and serum levels of LDH, β₂-MG and SF were detected. The patients were divided into death group and survival group according to their survival status, and the serum levels of LDH, β₂-MG and SF as well as the modified WPSS score were compared between the two groups. The risk factors for poor prognosis in MDS patients and the predictive values of serum LDH, β₂-MG, SF and modified WPSS score alone and their combination for poor prognosis in MDS patients were analyzed.
Results
The incidence of poor prognosis in MDS patients was 40.20% (41/102). The serum levels of LDH, β₂-MG and SF, the modified WPSS score, and the ratio of adverse karyotype prognosis in the death group were significantly higher than those in the survival group (P < 0.05). The results of Cox regression model analysis showed that elevated serum levels of LDH, β₂-MG and SF, elevated modified WPSS score, and adverse karyotype prognosis were risk factors for poor prognosis in MDS patients (P < 0.05). The results of receiver operating characteristic (ROC) curve analysis showed that the combination of serum LDH, β₂-MG, SF levels and modified WPSS score had a sensitivity of 95.12% and an area under the curve (AUC) of 0.918 for predicting poor prognosis in MDS patients, which were significantly higher than those of each indicator alone (P < 0.05).
Conclusion
Serum LDH, β₂-MG, SF levels and modified WPSS score have certain predictive value for poor prognosis in MDS patients, but the combined prediction value of the four indicators is higher.
- lactate dehydrogenase,
- β₂-microglobulin,
- ferritin,
- modified WHO-based Prognostic Scoring System,
- myelodysplastic syndrome,
- prognosis

FullText(HTML)

References (21)

References

[1]	YANG X C, MA L, ZHANG X Y, et al. Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia[J]. Exp Hematol Oncol, 2022, 11(1): 11. doi: 10.1186/s40164-022-00263-4
[2]	SAUTA E, ROBIN M, BERSANELLI M, et al. Real-world validation of molecular international prognostic scoring system for myelodysplastic syndromes[J]. J Clin Oncol, 2023, 41(15): 2827-2842. doi: 10.1200/JCO.22.01784
[3]	李璘, 聂玲, 于明华, 等. 基于常规实验室检查指标的改良WPSS预后积分系统对骨髓增生异常综合征预后判断意义的初步研究[J]. 中华血液学杂志, 2009, 30(5): 313-317. doi: 10.3760/cma.j.issn.0253-2727.2009.05.008
[4]	YANAGISAWA H, KAWABATA H, UEDA Y, et al. Prognostic impacts of serum levels of C-reactive protein, albumin, and total cholesterol in patients with myelodysplastic syndromes[J]. Int J Hematol, 2022, 116(1): 81-88. doi: 10.1007/s12185-022-03321-z
[5]	张佩芸, 蒋旭, 孙群英, 等. 骨髓增生异常综合征患儿血清LDH、β₂-MG、SF和维生素B12的表达及意义[J]. 中国妇幼健康研究, 2022, 33(1): 19-23. https://www.cnki.com.cn/Article/CJFDTOTAL-SANE202201004.htm
[6]	BAI Z M, LI L Y, GUAN T, et al. Clinical prognosis and bioinformatic analysis of primary thyroid lymphoma[J]. Medicine, 2021, 100(6): e24598. doi: 10.1097/MD.0000000000024598
[7]	HU Y Z, LIN J, WANG Y, et al. Identification of serum feRRitin-specific nanobodies and development towards a diagnostic immunoassay[J]. Biomolecules, 2022, 12(8): 1080. doi: 10.3390/biom12081080
[8]	何广胜. 世界卫生组织2016年骨髓增生异常综合征分类更新解读[J]. 中国实用内科杂志, 2016, 36(8): 643-646. https://www.cnki.com.cn/Article/CJFDTOTAL-SYNK201608008.htm
[9]	王化泉, 杨丽艳, 邵宗鸿. 骨髓增生异常综合征最低诊断标准(2017)解读[J]. 天津医药, 2018, 46(8): 811-814. https://www.cnki.com.cn/Article/CJFDTOTAL-TJYZ201808007.htm
[10]	肖志坚. 骨髓增生异常综合征诊断与治疗专家共识(解读)[J]. 临床内科杂志, 2014, 31(3): 210-211. doi: 10.3969/j.issn.1001-9057.2014.03.027
[11]	冉俊丽, 韩伟. 地西他滨治疗骨髓增生异常综合征的疗效分析[J]. 实用临床医药杂志, 2020, 24(18): 103-105. doi: 10.7619/jcmp.202018027
[12]	陈春平, 王娟, 徐徐. 骨髓增生异常综合征患者血清LDH、β₂-MG、铁蛋白、维生素B₁₂变化与预后的关系[J]. 标记免疫分析与临床, 2021, 28(4): 647-650, 691. https://www.cnki.com.cn/Article/CJFDTOTAL-BJMY202104026.htm
[13]	LEE P, YIM R, YUNG Y, et al. Molecular targeted therapy and immunotherapy for myelodysplastic syndrome[J]. Int J Mol Sci, 2021, 22(19): 10232. doi: 10.3390/ijms221910232
[14]	BERSANELLI M, TRAVAGLINO E, MEGGENDORFER M, et al. Classification and personalized prognostic assessment on the basis of clinical and genomic features in myelodysplastic syndromes[J]. J Clin Oncol, 2021, 39(11): 1223-1233. doi: 10.1200/JCO.20.01659
[15]	叶佳鑫, 钱文斌. 老年骨髓增生异常综合征患者的临床预后及影响因素分析[J]. 中华老年医学杂志, 2017, 36(9): 983-986. doi: 10.3760/cma.j.issn.0254-9026.2017.09.011
[16]	姚玉, 朱晖. 血清EPO、Hepcidin水平与骨髓增生异常综合征异基因造血干细胞移植预后的相关性[J]. 医学临床研究, 2022, 39(3): 335-339.
[17]	李雯雯, 李燕, 王晓敏. 血清学指标联合骨髓形态学分析对骨髓增生异常综合征的预后判断价值[J]. 中国全科医学, 2013, 16(38): 3789-3793. https://www.cnki.com.cn/Article/CJFDTOTAL-QKYX201338011.htm
[18]	王佩, 董照, 杨艳敏. 阿扎胞苷联合小剂量阿糖胞苷治疗中高危骨髓增生异常综合征患者的疗效及安全性[J]. 安徽医学, 2022, 43(10): 1126-1130. https://www.cnki.com.cn/Article/CJFDTOTAL-AHYX202210002.htm
[19]	谢杨, 汪丹, 刘建会. 骨髓增生异常综合征贫血患者铁代谢、炎症指标与铁调素的关系及对病情转归的影响[J]. 临床误诊误治, 2022, 35(10): 58-62. https://www.cnki.com.cn/Article/CJFDTOTAL-LCWZ202210013.htm
[20]	唐元艳, 张利铭, 张江召, 等. 细胞发育异常在骨髓增生异常综合征患者预后评估中的价值[J]. 现代肿瘤医学, 2018, 26(11): 1759-1761. doi: 10.3969/j.issn.1672-4992.2018.11.027
[21]	邓琳, 刘文, 李英, 等. 骨髓增生异常综合征细胞遗传学特征与临床的关系[J]. 川北医学院学报, 2021, 36(6): 719-722. doi: 10.3969/j.issn.1005-3697.2021.06.09

[1]	MAO Tingting, JIANG Qiong, WANG Yan, MING Xia, LOU Yinghua. Correlations of serum transforming growth factor-β1 and insulin-like growth factor-1 with pathological features and postoperative recurrence in patients with adenomyosis[J]. Journal of Clinical Medicine in Practice, 2025, 29(4): 103-107. DOI: 10.7619/jcmp.20243572
[2]	HOU Guoqing, YUE Hailong, CHANG Qian, MA Juntao. Effect of dexmedetomidine on epidural fibrosis afterspinal surgery in rats via the transforming growth factor-β1 pathway[J]. Journal of Clinical Medicine in Practice, 2025, 29(1): 77-82. DOI: 10.7619/jcmp.20243181
[3]	RAN Qian, FAN Chonggui, MA Weifeng, LI Shuaiqi. Associations of serum transforming growth factor-β1 and klotho expression levels with disease severity and cognitive function in patients with epilepsy[J]. Journal of Clinical Medicine in Practice, 2025, 29(1): 56-60. DOI: 10.7619/jcmp.20241976
[4]	CUI Xiaojing, ZHAO Chunmei, YANG Bo. Expression and significance of serum insulin-like growth factor binding protein-7 and silencing information regulator 4 in patients with acute heart failure[J]. Journal of Clinical Medicine in Practice, 2024, 28(3): 74-78, 83. DOI: 10.7619/jcmp.20232118
[5]	JIANG Mingxia, WANG Yu, LYU Guilan, ZHOU Yinan, DONG Xingyuan, XU Qi, ZHENG Jinfeng. Effect of essential fatty acids by MCP-1/TGF-β₁/COL-Ⅰ pathways for human kidney 2 cells with sugar damage[J]. Journal of Clinical Medicine in Practice, 2022, 26(13): 1-6, 40. DOI: 10.7619/jcmp.20220397
[6]	GUI Zhaohua, WU Jing, LI Xiaojie, YAN Hong. Expression of bone morphogenetic protein 9 and insulin-like growth factor-1 in different molecular subtypes of breast cancer and their correlations with clinical features[J]. Journal of Clinical Medicine in Practice, 2021, 25(8): 1-5, 10. DOI: 10.7619/jcmp.20210079
[7]	LI Fei, TANG Ping. Efficacy of pernasal intermittent positive pressure ventilation combined with high-dose bovine lung surfactant in the treatment of severe neonatal respiratory distress syndrome[J]. Journal of Clinical Medicine in Practice, 2020, 24(14): 71-75. DOI: 10.7619/jcmp.202014019
[8]	WANG Ruozhang, JIN Jian. Expression and purification of recombinant human bone morphogenetic protein 10 and it cardiac protection effect[J]. Journal of Clinical Medicine in Practice, 2019, 23(21): 1-6,17. DOI: 10.7619/jcmp.201921001
[9]	ZHU Chun, HUANG Haidong, WANG Lirui, GUO Zhiyong. Influence of heme oxygenase-1 on expressions of transforming growth factor-β1 and fibronectin in peritoneal mesothelial cells of rats induced by high glucose[J]. Journal of Clinical Medicine in Practice, 2014, (1): 1-4. DOI: 10.7619/jcmp.201401001
[10]	SHAO Weibin, ZHU Li, GU Lin, XIA Chunying, LI Xin, XUN Kang, FENG Songtao. Effect of bone morphogenetic protein-7 on advanced glycation end products induced epithelial-to-mesenchymal transition of rat peritoneal mesothelial cells[J]. Journal of Clinical Medicine in Practice, 2012, (22): 9-13.

Cited By

Cited by

Periodical cited type(7)

1.	刘娟，王凤兰. 川崎病患儿冠状动脉病变的影响因素分析及预测模型构建. 国际医药卫生导报. 2025(01): 60-65 .
2.	刘威，张兰. 婴儿川崎病冠状动脉病变的临床特点及危险因素分析. 分子诊断与治疗杂志. 2025(01): 38-40+45 .
3.	徐树红，姜军. 川崎病患儿冠脉病变发生的危险因素模型构建及分析. 医学理论与实践. 2024(13): 2290-2292 .
4.	张春燕. 白细胞介素-6/白蛋白比值与川崎病患儿冠状动脉损害的相关性研究. 中国实用医刊. 2023(11): 16-20 .
5.	高健，陈雨青. 川崎病患儿发生血管损伤的影响因素. 血管与腔内血管外科杂志. 2023(07): 846-849+863 .
6.	田慧，郝晓燕，祁洁，李莉，郭瑞霞，尉志红. 儿童川崎病的危险因素分析及列线图模型构建. 中西医结合心脑血管病杂志. 2023(17): 3278-3280 .
7.	张惠，张晓斌，陈俊义. 川崎病患儿急性期血脂水平与冠脉病变关系的研究. 中国卫生标准管理. 2023(24): 23-27 .

Other cited types(2)

Get Citation

PDF

XML

Article views (117) PDF downloads (6) Cited by(9)

Turn off MathJax

Article Contents

Abstract

References

Value of serum lactate dehydrogenase, β₂ microglobulin and ferritin combined with modified WHO-based Prognostic Scoring System in predicting poor prognosis of myelodysplastic syndrome